EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of the programmed death protein 1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischaemia

Tamás G Gergely, Zsófia D Drobni, Tamás Kovács, Nabil V Sayour, Viktória E Tóth, Márton S Kocsis iD, Zsófia Onódi, Gábor M Mórotz, Andrea Kovács, Daniel A Zlotoff iD, Hannah K Gilman, Jingyi Gong und 10 weitere

Cardiovascular Research · 05.06.2026 · 122 (8) · 1055-1069

DOI: 10.1093/cvr/cvag085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 22.04.2026. Verfasst von Tamás G Gergely und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest 1089, Hungary. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Heart Failure, Programmed Cell Death 1 Receptor, Myocardial Ischemia. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 Research and Innovation Programme, Hungarian Academy of Sciences, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, their use often leads to cardiovascular adverse effects, including cardiac dysfunction. Here, we hypothesized that a prior cardiac ischaemic injury could exacerbate cardiac dysfunction due to anti-programmed death protein 1 (PD-1) treatment. Furthermore, we investigated whether abatacept, a T-cell costimulation blocker, could ameliorate the ICI-induced cardiotoxicity in a pre-clinical model. Methods and results In a pre-clinical study, mice were treated with isoprenaline or control to induce reversible cardiac ischaemia. After 16 weeks of follow-up, recovery of cardiac function was confirmed via echocardiography, and mice from both groups were randomly treated with isotype control, anti-PD-1, or anti-PD-1 combined with abatacept, for 2 further weeks. Mice with prior ischaemic injury and anti-PD-1 treatment showed cardiac dysfunction with increased infiltration of T cells and macrophages and elevated expression of pro-inflammatory cytokines. Conversely, cardiac dysfunction and inflammation were less pronounced after anti-PD-1 treatment in mice without prior ischaemic injury. Mice with concomitant abatacept treatment exhibited normal cardiac function and alleviated pro-inflammatory response. In a parallel single-centre retrospective clinical cohort study, 1671 cancer patients receiving PD-1 inhibitors were analysed. Cases were defined as patients who developed incident heart failure (HF) after ICI initiation with a primary aim to test whether pre-existing ischaemic heart disease was associated with an increased risk for HF development post-ICI therapy. Sensitivity analyses included propensity score matching and comparison with non-ICI-treated cancer patients. Among ICI-treated patients, 109 (6.5%) developed HF over a median follow-up of 332 days. Multivariable logistic regression of the matched population showed increased odds of incident HF in patients with prior ischaemic cardiac events (odds ratio 2.11, 95% confidence interval 1.05–4.2, P = 0.033).

Conclusion

In mice, induction of cardiac inflammation and dysfunction by anti-PD-1 therapy was potentiated by prior transient ischaemic cardiac injury, which was ameliorated by abatacept cotreatment. Cancer patients with pre-existing ischaemic heart disease may be at greater risk for developing ICI-induced new-onset HF. Based on our findings, cardiac surveillance should be considered in patients starting ICI therapy with a prior history of ischaemic heart disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsHeart FailureProgrammed Cell Death 1 ReceptorMyocardial IschemiaAbataceptAnimalsHumansDisease Models, AnimalMaleCardiotoxicityMice, Inbred C57BLVentricular Function, LeftFemaleMiceRisk FactorsMiddle Aged

Stichwörter der Autor:innen

CardiotoxicityHeart failureImmune checkpoint inhibitorImmune-related adverse event

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAbataceptPdcd1 protein, mousePDCD1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest 1089, Hungary.
  • Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest 1089, Hungary.
  • HCEMM-SU Cardiometabolic Immunology Research Group, Budapest 1089, Hungary.
  • MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest 1089, Hungary.
  • Heart and Vascular Center, Semmelweis University, Budapest 1122, Hungary.
  • Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: Márton S Kocsis, Daniel A Zlotoff, Béla Merkely, Kerry L Reynolds, Zoltán V Varga

Förderung

  • European Union's Horizon 2020 Research and Innovation Programme
  • Hungarian Academy of Sciences
  • European Union
  • National Research, Development and Innovation Office
  • University Research Scholarship Programme of the Ministry for Culture and Innovation
  • National Research, Development and Innovation Fund
  • Gedeon Richter Talentum Foundation's
  • National Research, Development, and Innovation Office

Zitieren

APA

Gergely, T. G., Drobni, Z. D., Kovács, T., Sayour, N. V., Tóth, V. E., Kocsis, M. S., Onódi, Z., Mórotz, G. M., Kovács, A., Zlotoff, D. A., Gilman, H. K., Gong, J., Fekete, N., Pállinger, É., Buzás, E. I., Yousif, L. I., Meijers, W. C., Merkely, B., Reynolds, K. L., …, & Varga, Z. V. (2026). Inhibition of the programmed death protein 1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischaemia. Cardiovascular Research, 122(8), 1055-1069. https://doi.org/10.1093/cvr/cvag085

Vancouver

Gergely TG, Drobni ZD, Kovács T, Sayour NV, Tóth VE, Kocsis MS, et al. Inhibition of the programmed death protein 1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischaemia. Cardiovascular Research. 2026;122(8):1055-1069. doi:10.1093/cvr/cvag085

BibTeX
@article{Gergely2026,
  author = {Gergely, Tamás G and Drobni, Zsófia D and Kovács, Tamás and Sayour, Nabil V and Tóth, Viktória E and Kocsis, Márton S and Onódi, Zsófia and Mórotz, Gábor M and Kovács, Andrea and Zlotoff, Daniel A and Gilman, Hannah K and Gong, Jingyi and Fekete, Nóra and Pállinger, Éva and Buzás, Edit I and Yousif, Laura I and Meijers, Wouter C and Merkely, Béla and Reynolds, Kerry L and Ferdinandy, Péter and Neilan, Tomas G and Varga, Zoltán V},
  title = {Inhibition of the programmed death protein 1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischaemia},
  journal = {Cardiovascular Research},
  year = {2026},
  volume = {122},
  number = {8},
  pages = {1055--1069},
  doi = {10.1093/cvr/cvag085}
}
Kostenlos starten →